TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer.

TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer.

In treating patients with castration resistant prostate cancer (CRPC), enzalutamide, the second-generation androgen receptor (AR) antagonist, is an accepted standard of care. However, clinical benefits are limited to a median time of 4.8 months because resistance inevitably emerges. To determine the...

Full description

Bibliographic Details
Main Authors: Geun Taek Lee, Jeffrey A Rosenfeld, Won Tae Kim, Young Suk Kwon, Ganesh Palapattu, Rohit Mehra, Wun-Jae Kim, Isaac Yi Kim
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0213488

Internet

https://doi.org/10.1371/journal.pone.0213488

Similar Items